Warning Letter Roundup & Recap – October 13, 2015
This article was originally published in The Gray Sheet
Executive Summary
An FDA investigator observed two different products with the same lot number at a manufacturer of cannulas and trocars; employees at Lusys Labs – a maker of in vitro diagnostic kits – handled and packaged coated membranes with bare hands; procedures at software-maker Merge Healthcare allowed for devices that hadn't fully completed design validation to be shipped to end users for clinical use on patients; and more. Six device warning letters were listed by FDA this week.
You may also be interested in...
Incyte Ready To Go For Approval Of Topical Ruxolitinib In Atopic Dermatitis
With positive data from two Phase III trials, Incyte hopes to file an NDA this year for topical Jakafi in mild-to-moderate AD.
Axcella Addresses Metabolic Disease Quickly With GRAS Candidates
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
Performance Issues With CDC’s COVID-19 Assay Reagent Slows Rollout Of Test Kits To US States
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: